Sumitomo Pharma Oncology

We are now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need. See pinned post for our new page and follow Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co, Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer Research Unit and Oncology Clinical Development Unit, will collectively be known as Sumitomo Pharma Oncology or SMP Oncology. SMP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Our robust and diverse pipeline spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology. SMP Oncology encompasses discovery research, external innovation, clinical development and commercialization. The company has teams in Lehi, Utah, Tokyo and Osaka, Japan as well as Cambridge, Massachusetts. At SMP Oncology, we believe in the power of science – and our people – to usher in breakthrough innovation that will positively impact patients with cancer today and for generations to come.